Clinical Trial Update: Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of GSP 301 nasal spray in children aged 6 to under 12 with seasonal allergic rhinitis; results posted after completi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• GSP 301 nasal spray

Snippet

Sponsor: Glenmark Specialty S.A. | Conditions: Seasonal Allergic Rhinitis (SAR) | Phase 3 | Status: COMPLETED | Results posted: 2019-10-08